Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Warrants	3 Months Ended
Mar. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Warrants	8. Warrants The Company recognized $237,768 in warrant expense for the three months ended March 31, 2021 included in selling, general and administration expense.

Warrants

3 Months Ended

Mar. 31, 2022

The Company recognized $237,768 in warrant expense for the three months ended March 31, 2021 included in selling, general and administration expense.